GR1003520B - Methods of use of fluoroquinolone compounds against nosocornial gram negative pathogenic bacteria - Google Patents

Methods of use of fluoroquinolone compounds against nosocornial gram negative pathogenic bacteria

Info

Publication number
GR1003520B
GR1003520B GR990100318A GR990100318A GR1003520B GR 1003520 B GR1003520 B GR 1003520B GR 990100318 A GR990100318 A GR 990100318A GR 990100318 A GR990100318 A GR 990100318A GR 1003520 B GR1003520 B GR 1003520B
Authority
GR
Greece
Prior art keywords
pathogenic bacteria
methods
nosocornial
gram negative
compounds against
Prior art date
Application number
GR990100318A
Other languages
Greek (el)
Inventor
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of GR1003520B publication Critical patent/GR1003520B/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxan compound against certain pathogenic bacteria, such as bacteria selected from the group consisting of : Acinetobacter spp., Enterbacteria spp., Procteus mirabilis, Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa.
GR990100318A 1999-09-22 1999-09-22 Methods of use of fluoroquinolone compounds against nosocornial gram negative pathogenic bacteria GR1003520B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR99100318 1999-09-22

Publications (1)

Publication Number Publication Date
GR1003520B true GR1003520B (en) 2001-01-22

Family

ID=10943920

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990100318A GR1003520B (en) 1999-09-22 1999-09-22 Methods of use of fluoroquinolone compounds against nosocornial gram negative pathogenic bacteria

Country Status (1)

Country Link
GR (1) GR1003520B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0688772A1 (en) * 1994-06-16 1995-12-27 LG Chemical Limited Novel quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation
WO1998042705A1 (en) * 1997-03-21 1998-10-01 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0688772A1 (en) * 1994-06-16 1995-12-27 LG Chemical Limited Novel quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation
WO1998042705A1 (en) * 1997-03-21 1998-10-01 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AHN ET AL.: "In vivo efficacy of LB20304a against experimental respiratory tract infection in mice", YAKHAK HOECHI, vol. 40, no. 4, 1996, pages 438 - 441 *
CHEMICAL ABSTRACTS, vol. 125, no. 19, 1996, Columbus, Ohio, US; abstract no. 237657g, page 43; column 237661; XP002146746 *
CORMICAN ET AL.: "Antimicrobial activity and spectrum of LB20304, a new fluoronaphthyridone", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 41, no. 1, January 1997 (1997-01-01), pages 204 - 211, XP000911943 *
CORMICAN ET AL.: "Comparative antimicrobial and spectrum activity of LB20304a, a new fluorinated naphthoquinone compound", ABSTRACT 36TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 36, 15 September 1996 (1996-09-15) - 18 September 1996 (1996-09-18), new orleans, louisana, pages 109, XP000861831 *
ERWIN ET AL.: "Studies to establish quality control ranges for SB-265805 (LB20304) when using National Committee for laboratory standards antimicrobial susceptibility test methods", J. CLIN. MICROBIAOL., vol. 37, no. 1, January 1999 (1999-01-01), pages 279 - 280, XP000861920 *
FINLAY ET AL.: "SB-265805 (LB20304a): use of the Etest to determine the minimum inhibitory concentration against 378 clinical isolates", ABSTRACT 38TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 38, 1998, san diego, california, pages 257, XP000861828 *
HONG ET AL.: "Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl) pyrrolidine; Synthesis and antibatcerial activity of 7-(4-(aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)- 1-cyclopropyl-6fluoro-4-oxo-1,4-dihydro[1,8]naphathyridine- 3-carboxylic acid (LB20304)", J. MED. CHEM., vol. 40, no. 22, 24 October 1994 (1994-10-24), pages 3584 - 3593, XP000911756 *
KIM ET AL.: "In vitro activities of LB20304, a new fluoroquinolone", ARCH. PHARMACAL RES., vol. 19, no. 1, 1996, pages 52 - 59, XP000911954 *
MARCO ET AL.: "Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria", J. ANTIMICROBIAL CHEMOTHER., vol. 40, no. 4, 1997, pages 605 - 607, XP000911923 *
OH ET AL.: "In vitro and in vivo antibacterial activities of LB20304a, a new fluoronaphthyridone", 35TH INTERNATIONAL CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 17 September 1995 (1995-09-17) - 20 September 1995 (1995-09-20), san francisco, pages 148, XP000861824 *
OH ET AL.: "In vitro and in vivo antibacterial activities of LB20304a, a new fluoronaphthyridone", ANTIMICROBIAL AGENTS CHEMOTHER., vol. 40, no. 6, June 1996 (1996-06-01), pages 1564 - 1568, XP000911979 *
PAECK ET AL.: "Bactericidal activities of LB20304, a new fluoroquinolone", ARCH. PHARMACAL RES., vol. 19, no. 4, 1996, pages 317 - 320, XP000911955 *
PAECK ET AL.: "SB-265805 (LB20304a): In vitro antibacterial activity and spectrum", ABSTRACT 38TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 38, 24 September 1998 (1998-09-24) - 27 September 1998 (1998-09-27), san diego, california, pages 255, XP000861826 *

Similar Documents

Publication Publication Date Title
AU2003291227A1 (en) Antibacterial agents
TW200507841A (en) Antibacterial agents
WO2004058144A3 (en) Antibacterial agents
IS7214A (en) Compositions comprising the cephalosporin compound and their use in the treatment of bacterial infections in cats and dogs
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
WO2006055070A3 (en) Novel lincomycin derivatives possessing antibacterial activity
AU4562397A (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
EP1560821A4 (en) Antibacterial agents
YU102503A (en) Fused pyrimidine dhfr inhibitors as antibacterials
NZ545472A (en) 7-(4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl)quinolonecarboxylic acid derivative
EP1037650A4 (en) Methods and compositions for the treatment and prevention of staphylococcus aureus infections
WO2006025634A8 (en) 2-arylmethylazetidine carbapenem derivatives and preparation thereof
WO2005012320A3 (en) Novel lincomycin derivatives possessing antimicrobial activity
WO2004050036A3 (en) Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
EP1223935A4 (en) Methods of use of fluoroquinolone compounds against bacteria
WO2004016632A8 (en) Lincomycin derivatives possessing antibacterial activity
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
WO2004034961A3 (en) Antimicrobial agents and uses thereof
CA2380455A1 (en) 9a-azalides with antibacterial activity
GR1003520B (en) Methods of use of fluoroquinolone compounds against nosocornial gram negative pathogenic bacteria
AU2002223796A1 (en) Pleuromutilin derivatives with antimicrobial activity
WO2005007665A3 (en) Lincomycin derivatives possessing antibacterial activity
EP1561465A3 (en) Methods of use of fluoroquinolone compounds against bacteria
EP1439840A4 (en) Monobactam antibacterial compounds and methods of use thereof
CA2281817A1 (en) Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees
ML Lapse due to non-payment of fees